Suvarna Garge

ABT 239

Updated on
Share on FacebookTweet on TwitterShare on LinkedIn
CAS Number  460746-46-7
IUPHAR/BPS  1218
ChEMBL  CHEMBL351231
Molar mass  330.42 g/mol
PubChem CID  9818903
ChemSpider  7994652
Formula  C22H22N2O
ABT-239

ABT-239 is an H3-receptor inverse agonist developed by Abbott. It has stimulant and nootropic effects, and has been investigated as a treatment for ADHD, Alzheimer's disease, and schizophrenia. ABT-239 is more active at the human H3 receptor than comparable agents such as thioperamide, ciproxifan, and cipralisant. It was ultimately dropped from human trials after showing the dangerous cardiac side effect of QT prolongation, but is still widely used in animal research into H3 antagonists / inverse agonists.

References

ABT-239 Wikipedia


Similar Topics
Shubhakankshalu
Barry Bannan
David Plouffe
Topics